Hygiena 2012, 57(2):56-59

Inflammation as a Risk Factor for the Development of Insulin Resistance

Dagmar Horáková, Helena Kollárová, Kateřina Azeem, Vladimír Janout
Univerzita Palackého v Olomouci, Lékařská fakulta, Ústav preventivního lékařství, Olomouc

C-reactive protein (CRP) is a sensitive marker of inflammation. It has been shown to be potentially useful as an indicator for predicting the risk of metabolic syndrome, based on the development of insulin resistance. The study verified CRP levels in selected groups of individuals and their correlations with parameters typical for insulin resistance. The following groups were studied: healthy individuals (A, n=126), obese individuals (B, n=213) and patients diagnosed with metabolic syndrome (C, n=79). Obese persons in Group B had parameters suggestive of early insulin resistance: hypertension, hyperglycaemia, QUICKI (0.305), lower adiponectin and higher aFABP levels as compared with the healthy subjects. Group C individuals were diagnosed with metabolic syndrome, as evidenced by the QUICKI markers for insulin resistance (0.293), much lower adiponectin (7.3 mg/L) and high aFABP levels (35.3 mg/L). CRP concentrations were lowest in Group A healthy individuals (0.75 mg/L), higher in Group B obese subjects (2.65 mg/L) and highest in Group C patients with metabolic syndrome (3.62 mg/L). The highest correlations were between CRP and aFABP (0.46) and between aFABP and Body Mass Index (0.57). The pathophysiology of insulin resistance is contributed to by subclinical inflammatory reaction, mainly expressed in visceral adipose tissue. Obese individuals were found to have CRP concentrations different from those in healthy individuals, approaching the level of 3 mg/L, known as the risk level. Individuals with metabolic syndrome had risk CRP levels. The presence of obesity in association with increased CRP levels is considered a significant predictor of the gradual development of metabolic syndrome.

Keywords: diabetes mellitus prevention, metabolic syndrome prevention, obesity, disease prevention

Received: October 2011; Accepted: February 20, 2012; Published: June 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horáková D, Kollárová H, Azeem K, Janout V. Inflammation as a Risk Factor for the Development of Insulin Resistance. Hygiena. 2012;57(2):56-59.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kolb H, Mandrup-Poulsen T. The global diabetes epidemic as a consequence of lifestyle-induced low-grade inflammation. Diabetologia. 2010 Jan;53(1):10-20. Go to original source... Go to PubMed...
    2. Škrha J. Diabetes mellitus 2. typu jako subklinický zánět. Čas Lék Čes. 2010;149(6):277-81.
    3. National Institutes of Health. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). NIH publication No. 02-5215 [Internet]. Bethseda (MD): National Institutes of Health (US); 2002 [cited 2011 Sep 27]. Available from: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf.
    4. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000 Jul;85(7):2402-10. Go to original source... Go to PubMed...
    5. Češka R. Zánět. In: Svačina Š. Poruchy metabolismu a výživy. Praha: Galén; 2010. p. 290.
    6. Svačina Š. Výskyt metabolického syndromu. In: Svačina Š. Poruchy metabolismu a výživy. Praha: Galén; 2010. p. 229.
    7. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: joint scientific statement. Circulation. 2009 Oct;120(16):1640-5. Go to original source... Go to PubMed...
    8. Kintscher U, Hartge M, Hess K, Foryst-Ludwig A, Clemenz M, Wabitsch M, et al. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol. 2008 Jul;28(7):1304-10. Go to original source... Go to PubMed...
    9. Hamdy O, Porramatikul S, Al-Ozairi E. Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr Diabetes Rev. 2006 Nov;2(4):367-73. Go to original source... Go to PubMed...
    10. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J. 2004 Nov;68(11):975-81. Go to original source... Go to PubMed...
    11. Bronský J, Nevoral J, Průša R. Adiponektin - marker inzulinové senzitivity. Česk Fyziol. 2005;54(3):92-6.
    12. Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol. 2009 Jun;20(3):182-9. Go to original source... Go to PubMed...
    13. Kahn SE, Haffner SM, Viberti G, Herman WH, Lachin JM, Kravitz BG, et al; Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2010 Jan;33(1):177-83. Go to original source... Go to PubMed...
    14. Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem. 2006 Mar;52(3):405-13. Go to original source... Go to PubMed...
    15. Tso AW, Xu A, Sham PC, Wat NM, Wang Y, Fong CH, et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care. 2007 Oct;30(10):2667-72. Go to original source... Go to PubMed...
    16. Stefanska A, Sypniewska G, Blaszkiewicz B, Ponikowska I, Cwiklinska-Jurkowska M. Comparison between C-reactive protein and adipocyte fatty acid-binding protein as a component of metabolic syndrome in middle-aged women. Clin Biochem. 2011 Mar;44(4):304-6. Go to original source... Go to PubMed...

    Return to the content